As the most commonly occurring cancer in women worldwide, breast cancer poses a
formidable public health challenge on a global scale. Breast cancer consists of a group of …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

Triple-negative breast cancer (TNBC) is an aggressive subtype associated with early
metastatic recurrence and worse patient outcomes. TNBC tumors express molecular …

Rapidly proliferating tumor and immune cells need metabolic programs that support energy
and biomass production. The amino acid glutamine is consumed by effector T cells and …

Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most
aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl …

Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are
often aggressive and associated with a poor prognosis. Molecular characterization, while …

Purpose Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors
comprising various breast cancers simply defined by the absence of estrogen receptor …

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers,
does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …